Neuropsychobiology最新文献

{"title":"Circadian and sleep-related polygenic scores in relation to lithium treatment response in bipolar disorder.","authors":"Marina Zafrilla-López, Daniel Herrera-Escartín, Maria Guardiola-Ripoll, Arnau García-Fernández, Miriam Acosta-Díez, Anna Giménez-Palomo, Pilar A Saiz, Maria Paz García-Portilla, Esther Jiménez, Sergi Papiol, Lourdes Fañanás, Victoria Ruiz, Patricia Gavín, Leticia González-Blanco, Eduard Vieta, Thomas G Schulze, Mar Fatjó-Vilas, Antoni Benabarre, Marina Mitjans, Bárbara Arias","doi":"10.1159/000551565","DOIUrl":"https://doi.org/10.1159/000551565","url":null,"abstract":"<p><p>Introduction Circadian rhythms are reflected through sleep-wake patterns and chronotype. Patients with bipolar disorder (BD) frequently exhibit disrupted sleep patterns, and a tendency for evening chronotype. Also, genetic risk factors for BD partially overlap with those influencing sleep traits. Lithium (Li), the first-line therapy for BD, stabilizes circadian rhythms and promotes morningness in responders. This study aimed to evaluate whether the polygenic burden of sleep-related traits is associated with Li response in BD patients. Methods A total of 114 European-ancestry BD patients were categorized as Li responders (N=79) or non-responders (N=35), based on the reduction of 50% of the episodes. Polygenic scores (PGS) for chronotype, daytime dozing, ease of getting up, insomnia, morningness, napping, sleep duration, and snoring were calculated using PRS-CS. Associations between each PGS and Li response were tested using logistic regression models. Comparisons were made between the extreme quartiles of each PGS. Results The polygenic score for ease of getting up was significantly associated with Li response, explaining 9.989% of the variance based on Nagelkerke's pseudo-R² (FDR-adjusted p-value= 0.046). Additionally, individuals with a higher genetic predisposition for ease of getting up had increased odds of a good response (FDR-adjusted p-value= 0.039; OR= 5.143; 95% CI= 1.537-17.209). Conclusion The study suggests that a higher genetic predisposition for ease of getting up in the morning may increase the likelihood of responding to Li treatment in BD patients. Our study aligns with previous evidence, highlighting the importance of sleep and chronotype patterns in response to Li in BD patients.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"1-18"},"PeriodicalIF":3.1,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CACNA2D2 rs56287038:G&gt;T and SCN1A rs2298771:C&gt;T Variants Are Associated with Antiseizure Medication Response in Turkish Epilepsy Patients : A Pilot Study.","authors":"Zeynep Gizem Todurga-Seven, Kubra Cigdem Pekkoc-Uyanik, Erhan Rasit Agay","doi":"10.1159/000551767","DOIUrl":"https://doi.org/10.1159/000551767","url":null,"abstract":"<p><strong>Introduction: </strong>Epilepsy is a chronic neurological disorder characterized by recurrent seizures, with variants in ion channel genes such as SCN1A, SCN1B, and CACNA2D2 implicated in neuronal excitability. This research aims to explore genetic polymorphisms in the SCN1A, SCN1B, and CACNA2D2 genes among Turkish epilepsy patients and assess their impact on responsiveness to antiseizure medications (ASMs).</p><p><strong>Methods: </strong>Targeted next-generation sequencing (tNGS) was applied to genomic DNA from 29 patients.</p><p><strong>Results: </strong>Common 15 variants were analyzed in CACNA2D2 (rs2239801, rs56287038), SCN1A (rs2298771, rs3032638, rs11394960, rs67636132, rs566839, rs1461193, rs6432861, rs2020318) and SCN1B (rs72556351, rs2278995, rs557140301, rs67701503, rs55742440). A statistically significant difference in ASM response was observed in the recessive model of SCN1A rs2298771: C>T (TT vs. CC+CT) (p=0.044), with the TT genotype associated with improved response. CACNA2D2 rs56287038:G>T showed significance in the allelic model (p=0.012); the T allele was found only in resistant patients. SCN1A haplotype analysis revealed reduced C allele frequency in responders (p=0.041). The CT (rs2298771+rs2020318), CG (rs2298771+rs1461193), and CC (rs2298771+rs6432861) haplotypes also showed considerable differences among groups (p=0.041, p=0.023, p=0.041, respectively). Moreover, CTG (rs2298771+rs2020318+rs1461193), CCG (rs2298771+rs6432861+rs1461193), and CTCG (rs2298771+rs2020318+rs6432861+rs1461193) haplotypes were significantly associated with treatment response (p=0.023, p=0.023, p=0.022). However, none of these associations remained statistically significant after false discovery rate (FDR) correction, and all findings should therefore be interpreted as exploratory.</p><p><strong>Conclusion: </strong>CACNA2D2 rs56287038:G>T and SCN1A rs2298771:C>T may effect ASM response.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"1-21"},"PeriodicalIF":3.1,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147654673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association of Kynurenine Pathway Metabolites with Neurocognitive Function in Unaffected Offspring of Parents with Bipolar Disorder.","authors":"Gökçeçiçek Arıcı Sağlıyan, Fatih Hilmi Çetin, Fikret Akyürek, Özlem Çiçek Zekey, Serhat Türkoğlu, Halit Necmi Uçar, Bahadır Öztürk, Kürşat Altınbaş","doi":"10.1159/000551769","DOIUrl":"https://doi.org/10.1159/000551769","url":null,"abstract":"<p><strong>Introduction: </strong>The study aimed to investigate whether alterations in tryptophan (TRP) metabolites reflect dysregulation of the kynurenine pathway, which has been implicated in bipolar disorder (BD) and to examine their relationship with cognitive functioning by assessing TRP metabolite levels alongside executive performance in non-affected offspring of individuals diagnosed with BD.</p><p><strong>Methods: </strong>The study included 32 healthy offspring of parents with BD Type I as the case group and 31 healthy offspring of parents without any psychiatric disorders as controls. Psychiatric screening was conducted using the Turkish adaptation of the Schedule for Affective Disorders and Schizophrenia for School Age Children - Present and Lifetime Version (K-SADS-PL-DSM-5). Executive functioning was examined using a neuropsychological battery that included the Stroop, Serial Digit Learning (SDLT), and Cancellation (CT) tests. Serum levels of TRP, kynurenine (KYN), kynurenic acid (KYNA), 3-hydroxykynurenine (3-HK), and 3-hydroxyanthranilic acid (3-HAA), as well as metabolite ratios (KYN/TRP, KYNA/KYN, 3-HK/KYN, and KYNA/3-HK), were measured. Logistic regression analysis was applied as part of the statistical approach to evaluate whether these metabolites and ratios could distinguish the offspring of individuals with bipolar disorder from healthy controls.</p><p><strong>Results: </strong>Neurocognitive performance was significantly poorer in the case group than in the control group. Serum levels of TRP (t=3.568, p=0.001), KYN (t=3.772, p=0.001), KYNA (t=2.797, p=0.007), and the ratios of KYN/TRP (t=2.550, p=0.014) and KYNA/3-HK (z=-2.557, p=0.011) were significantly decreased in cases, whereas KYNA/KYN (t=-2.562, p=0.013) and 3-HK/KYN (z=-3.368, p=0.001) ratios were significantly elevated. Correlation analyses showed significant associations between executive function deficits and TRP (r=0.367, p=0.039), KYN (r=0.380, p=0.032), KYNA (r=0.488, p=0.005), 3-HK (r=0.492, p=0.004), and the 3-HK/KYN ratio (r=0.408, p=0.020). Logistic regression analysis indicated that lower KYN levels distinguished cases from controls (OR=0.986, 95% CI=0.978-0.995, p=0.002).</p><p><strong>Conclusions: </strong>The findings indicate that metabolism within the kynurenine pathway in the offspring of individuals with bipolar disorder shows a shift toward its neurotoxic branch, reflected by increased 3-HK/KYN ratios and decreased KYNA-related indices, and this was associated with deficits in executive functioning. These findings indicate that alterations in TRP metabolism may play a role in altered cognitive processing among individuals with a familial predisposition to BD. Further research employing larger cohorts and dimensional analyses is needed to elucidate these relationships more precisely.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"1-22"},"PeriodicalIF":3.1,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147654684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An increase in C-reactive protein levels during antidepressant treatment as a candidate marker for treatment non-response in major depressive disorder.","authors":"Marius Solon Etzel, Yevgenia Rosenblum, Martin Dresler, Axel Steiger, Thorsten Mikoteit, Marcel Zeising","doi":"10.1159/000551623","DOIUrl":"https://doi.org/10.1159/000551623","url":null,"abstract":"<p><p>Introduction One-third of patients with major depressive disorder (MDD) exhibit low-grade inflammation as reflected by C-reactive protein (CRP) concentrations > 3 mg/L. We explored whether CRP changes from baseline to week one of antidepressant treatment (ΔCRP) can serve as a marker of treatment response. Methods CRP serum levels were measured at baseline and after the first week of treatment in 33 MDD patients and correlated with patients' Hamilton depression scale (HAM-D), while adjusting for age, gender and body mass index. We assessed antidepressant responses at weeks one and four of treatment as a > 25% and > 50% HAM-D score reduction (ΔHAM-D) compared to baseline, respectively. We compared baseline and week-one CRP levels with the paired t-test within responders and non-responders separately and ΔCRP between the groups with the ANCOVA. Results Higher ΔCRP correlated with lower week-four ΔHAM-D scores (r = -0.5, p = 0.006). Non-responders showed higher ΔCRP - but not baseline and week-one CRP - than responders (p = 0.018, Cohen's d = 1.1). A ΔCRP increase was observed in 13/16 (81%) non-responders and 7/17 (41%) responders (Fisher's exact test's p = 0.03). A ΔCRP increase combined with a week-one non-response was observed in 13/16 (81%) non-responders and 1/17 (6%) responders (p < 0.0001). Conclusions Rather ΔCRP at week one than baseline CRP might be indicative of treatment response at week four, especially if combined with week-one ΔHAM-D. In the future, ΔCRP could be introduced into psychiatric practice to guide treatment plans.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"1-23"},"PeriodicalIF":3.1,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147581802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The network ties between sleep quality, suicidality, and psychopathology.","authors":"Corinna Slanitz, Jürgen Fuchshuber, Sabrina Mörkl, Jolana Wagner-Skacel, Human Unterrainer","doi":"10.1159/000551597","DOIUrl":"https://doi.org/10.1159/000551597","url":null,"abstract":"<p><strong>Introduction: </strong>In recent years, growing attention has been given to the role of sleep disturbances in mental health outcomes, assuming a potential link between sleep problems and suicidality. This study applies a network analysis to examine how sleep quality is interconnected with suicidal thoughts and behaviours, as well as with a range of psychopathological symptoms.</p><p><strong>Methods: </strong>A total sample of 1674 participants (75.3% female, 24.7% male) from the general population were investigated and completed standardized assessments of sleep quality and psychopathological symptoms. A regularized cross-sectional partial correlation network between sleep quality (PSQI), suicidality (SSEV) and psychopathological symptoms (BSI-18) was estimated using the EBICglasso algorithm. Node centrality, predictability, and bridge centrality were evaluated, and bootstrap methods were employed to test the stability and significance of the network structure.</p><p><strong>Results: </strong>The network was found to be stable, supporting reliable interpretations. Active suicide thoughts, anxiety and subjective sleep quality where found to be the most influential nodes within the investigated psychopathological network. Depression and daytime impairment due to poor sleep quality were observed as nodes with the highest bridge centrality.</p><p><strong>Conclusions: </strong>These findings highlight that depression and, importantly, daytime functioning related to poor sleep quality play a central role in linking suicidality and sleep quality. This emphasizes the need to address not only nighttime sleep problems but also daytime impairments as key clinical targets. Prioritizing interventions that improve sleep and restore daytime functioning may therefore be crucial in suicide prevention and clinical care.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"1-20"},"PeriodicalIF":3.1,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147491304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Cognition in Bipolar Disorder: A Systematic Review of Current Pharmacological and Nutraceutical Approaches.","authors":"Nefize Yalin, Aysegul Yildiz","doi":"10.1159/000551232","DOIUrl":"https://doi.org/10.1159/000551232","url":null,"abstract":"<p><strong>Introduction: </strong>Cognitive impairment is a core feature of bipolar disorder (BD) that impacts functioning and quality of life. This review systematically summarizes the evidence on pharmacological and nutraceutical interventions for cognitive deficits in BD.</p><p><strong>Methods: </strong>A systematic search of MEDLINE, EMBASE, and PsycINFO was conducted to identify studies examining the efficacy of pharmacological or nutraceutical interventions on cognition in individuals aged 18-65 years with euthymic or partially remitted BD from inception to December 29, 2024. This review was registered with PROSPERO (Reference Number: CRD42024618397). Risk of bias assessment was conducted using the National Institutes of Health (NIH) quality assessment tools. The extracted data were summarized using a narrative synthesis approach.</p><p><strong>Results: </strong>Sixteen studies were included, evaluating 13 different agents. Working memory, verbal learning and memory, executive functioning, social cognition, and attention/vigilance were improved by multiple agents. Galantamine showed replicated pro-cognitive effects on verbal learning and memory. Lithium, tianeptine, withania somnifera (ashwagandha), insulin, and lurasidone each demonstrated cognitive benefits in single studies. Erythropoietin and pramipexole showed mixed results across two studies. Methylene blue, JNJ-18038683, docosahexaenoic acid, modafinil, and quetiapine revealed no significant effects. The quality of the studies ranged from good to poor, and the safety and tolerability profiles of the agents were favorable.</p><p><strong>Discussion: </strong>These results suggest possible approaches for improving cognitive functioning in individuals with BD. Nevertheless, the inconsistency in outcomes and differences in study methodologies highlight the need for larger, rigorously controlled trials with uniform cognitive evaluations to confirm these findings and to assess their clinical relevance.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"1-24"},"PeriodicalIF":3.1,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147474314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnetoencephalographic Signatures of Facial Emotion Processing in Schizophrenia and Major Depressive Disorder: A Systematic Review.","authors":"Mauro Scala, Juergen Dukart, Giuseppe De Simone, Giuseppe Fanelli, Rocío Arroyo Iturra, Sara Bordignon, Chiara Fabbri, Alessandro Serretti","doi":"10.1159/000550903","DOIUrl":"10.1159/000550903","url":null,"abstract":"<p><strong>Introduction: </strong>Social withdrawal is a frequent marker of functional decline in schizophrenia, Alzheimer's disease (AD), and major depressive disorder (MDD), and is associated with deficits in facial-emotion recognition (FER). Magnetoencephalography (MEG) captures neuronal activity at millisecond resolution, enabling the assessment of fast oscillatory dynamics and functional connectivity during FER. This systematic review compares MEG responses during implicit and explicit FER tasks in adults with schizophrenia, AD, and MDD to identify possible transdiagnostic and disorder-specific alterations. However, no eligible studies were identified for AD.</p><p><strong>Methods: </strong>Following PRISMA guidelines, PubMed, Web of Science, and CINAHL were systematically searched from inception to February 2025 for MEG studies comparing adults with schizophrenia, AD, or MDD with healthy controls during implicit (i.e., passive viewing) or explicit (i.e., labeling) FER tasks.</p><p><strong>Results: </strong>Eighteen studies met inclusion criteria (four schizophrenia, 14 MDD, none in AD). Schizophrenia and MDD showed transdiagnostic MEG patterns across disorder-specific studies, including early temporal-cortical hyperactivation (50-150 ms) during implicit FER and early amygdala hyper-reactivity (within 100 ms) followed by prefrontal hypo-recruitment (100-500 ms) during explicit FER, with disrupted cortico-limbic connectivity. Schizophrenia was associated with specific increases in theta-gamma coupling and unidirectional visual-limbic-prefrontal connectivity during explicit FER. MDD showed a shift from early gamma hyper-synchrony (50-150 ms) to late beta/gamma hypo-synchrony (250-500 ms), with reduced fronto-limbic and fusiform-amygdala coupling.</p><p><strong>Conclusions: </strong>MEG reveals a transdiagnostic signature of FER dysfunction that may be linked to social withdrawal and disorder-specific oscillatory patterns that may inform targeted neuromodulation.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"1-21"},"PeriodicalIF":3.1,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147308323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Randomised Controlled Trial on the Efficacy of Ketamine versus Electroconvulsive Therapy in Severe Depression with Suicidal Ideation.","authors":"Lavanya Seth, Jitendriya Biswal, Surjeet Sahoo, Riya Shetty, Jamuna Das","doi":"10.1159/000550863","DOIUrl":"10.1159/000550863","url":null,"abstract":"<p><strong>Introduction: </strong>Severe depressive episodes with suicidal ideation present major therapeutic challenges and often require interventions beyond standard antidepressant therapy. Electroconvulsive therapy (ECT) remains a cornerstone treatment for refractory depression, while ketamine, an N-methyl-D-aspartate receptor antagonist, has emerged as a rapid-acting antidepressant with potential benefits in reducing suicidal ideation. This study compares the efficacy, onset of action, and tolerability of intravenous ketamine and ECT as adjunctive treatments in severe major depressive disorder with active suicidal ideation.</p><p><strong>Methods: </strong>A randomised controlled trial was conducted at a tertiary care psychiatry department in India, enrolling 64 patients aged 18-60 years with severe depression (HAM-D ≥19, SSI ≥4). Participants were randomly assigned to receive either intravenous ketamine (n = 31) or ECT (n = 33), alongside ongoing oral antidepressants. Both groups underwent six treatment sessions over 2 weeks. Outcomes were assessed at baseline, post-treatment, and 4 weeks after completion. Primary endpoints included changes in depression severity (HAM-D) and suicidal ideation (SSI), while secondary outcomes included response and remission rates, as well as safety and tolerability profiles.</p><p><strong>Results: </strong>Both ECT and ketamine significantly reduced depressive symptoms and suicidal ideation (p < 0.001). HAM-D scores declined from 27 to 1 in the ECT group and from 26 to 2 in the ketamine group by the 4-week follow-up. SSI scores showed parallel improvement, from 12.1 to 1.2 with ECT and 12.6 to 2.0 with ketamine. Ketamine demonstrated a faster onset of clinical improvement, while ECT showed slightly greater durability of response. Side effects were mild in both groups, though ECT was associated with transient cognitive impairment, whereas ketamine produced minor dissociative and urinary symptoms.</p><p><strong>Conclusion: </strong>Ketamine offers a faster reduction in suicidal ideation than ECT, making it a promising acute intervention. Both are effective, safe adjunctive therapies, with treatment choice guided by patient profile and tolerability.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"1-12"},"PeriodicalIF":3.1,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Participant Experience in a Study of Dietary Counselling plus Omega-3 Supplementation for the Treatment of Generalized Anxiety Disorder among Women: A Focus Group Study.","authors":"Monique Aucoin, Domenique Barbaro, Laura LaChance, Kieran Cooley","doi":"10.1159/000550697","DOIUrl":"10.1159/000550697","url":null,"abstract":"<p><strong>Introduction: </strong>Nutrition is an important determinant of health among people with mental disorders; however, barriers to dietary counselling exist. The Eating and Supplementation for Generalized Anxiety Disorder study (\"EASe-GAD\") was the first trial to assess the impact of these interventions on anxiety symptoms. The primary objective of the present companion qualitative study was to gather and analyze qualitative data about the acceptability, participant experience, impact, barriers and facilitators, strengths, and weaknesses of the EASe-GAD program while also identifying opportunities for improvement.</p><p><strong>Methods: </strong>Participants were eligible for this study if they participated in the EASe-GAD trial. Data were collected using focus groups which followed a semi-structured interview approach with a set of predetermined questions. The sessions were recorded and transcribed for data analysis. Data were analyzed by thematic analysis.</p><p><strong>Results: </strong>Three focus groups were completed, involving a total of 12 women. They reported a range of components that they found helpful, such as increased self-efficacy, as well as positive outcomes that they attributed to the intervention, such as improved mental and physical health. They reported components of the program that were less enjoyable, such as having their body weight measured, and also suggested opportunities for improvement. Many participants reported that cost implications of a diet intervention were an important consideration.</p><p><strong>Conclusion: </strong>This project provided valuable insight into the participant experience and impact of the pilot dietary counselling program. Participants reported benefits and opportunities for improvement for subsequent studies aimed at improving nutrition among people with anxiety disorders.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"1-15"},"PeriodicalIF":3.1,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13002229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146053100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Lithium Treatment and Sensory Processing Sensitivity in Bipolar Disorder Patients.","authors":"Ewa Ferensztajn-Rochowiak, Małgorzata Gałczyńska-Rusin, Natalia Grobelna, Janusz K Rybakowski, Filip Rybakowski","doi":"10.1159/000550155","DOIUrl":"10.1159/000550155","url":null,"abstract":"<p><strong>Introduction: </strong>Sensory processing sensitivity (SPS) describes innate temperament, which consists of three characteristics: ease of excitation (EOE), low sensory threshold (LST), and aesthetic sensitivity (AES). There has been no research on SPS in bipolar disorder (BD), nor the effect of treatment on these traits. Relations between temperament, personality, and the course of BD are complex and modify the effect of treatment. Long-term lithium treatment modifies course of the illness and excellent lithium responders are known from their unique clinical characteristic. The aim of the study was to examine the relation between pharmacological treatment and SPS in BD patients.</p><p><strong>Methods: </strong>The study group comprised 35 patients (F/M = 26/9) with BD, where 20 patients were diagnosed with BD type I and 15 patients with BD type II. Twenty patients were treated with lithium (16 ± 13 years) and fifteen with other mood stabilizers (14 ± 4 years). The comparison between groups included parameters: BD type, clinical characteristics (family history, suicidal attempts, duration of illness, duration of treatment), type of treatment and gender in relation to sensory sensitivity traits. The highly sensitive person scale (HSPS) including 27 items and distinguishing three parameters: EOE, LST, and AES were used. To assess quality of lithium treatment, the Alda scale was implemented.</p><p><strong>Results: </strong>Lithium-treated patients obtained significantly lower scores on HSPS total score (4.27 vs. 4.98, p = 0.009) and EOE (4.05 vs. 5.23, p = 0.002), compared to patients treated with other mood stabilizers. AES and LST remained on similar level in both groups (however, the results are limited by insufficient statistical power). Also, the negative correlation between LST score and Alda scale score was obtained (r = -0.484; p = 0.031). There was no difference according to clinical characteristics between BD I and BD II, as well as between males and females.</p><p><strong>Conclusions: </strong>Longitudinal treatment with lithium could reduce overall SPS traits, particularly \"EOE\". However, it is possible that low intensity of these traits is a factor in good response to lithium. Also, lithium treatment may not reduce aesthetic sensitivity, parameter related to creativity. \"Low sensory threshold\" can be considered as negative predictor of lithium treatment outcome.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"85-94"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146113913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}